JPRN-UMIN000011020招募中2 期
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer. - Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.
Sairtama Breast Cancer Clinical Study Group (SBCCSG)na0 个研究点目标入组 35 人开始时间: 2013年6月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)having systemic infection with a fever of 38 degrees or more 2)pleural effusion, ascites, or pericardial fluid requiring drainage 3)brain metastasis with clinical symptoms 4)patient with following serious complication ischaemic heart disease or heart disease such as arrhythmia not controllable by treatment myocardial infarction < 6 months prior to study entry hepatic cirrhosis interstitial pneumonia or pulmonary fibrosis bleeding tendency 5)having active double cancer 6)HER2 over-expressed 7)pregnancy, breast-feeding or women with childbearing potential 8)judged by the investigator not to be appropriate for the study
研究者
相似试验
进行中（未招募）
1 期
A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic canceradvanced pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2017-003621-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA25
已完成
2 期
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancerFirst-Line therapy for metastatic HER2-positive breast cancer.JPRN-UMIN000021585Sairtama Breast Cancer Clinical Study Group (SBCCSG)16
已完成
2 期
A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancerJPRN-UMIN000014107SONG (South Osaka Network Group for Breast Cancer)43
进行中（未招募）
1 期
Gemcitabine and Eribulin as first line treatment of advanced triple-negative breast cancer.EUCTR2012-003505-10-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA83
已完成
不适用
A Phase II Study of Eribulin Evaluating Efficacy and Safety as first or secondary line chemotherapy for advanced or metastatic breast cancer without HER2 overexpressingAdvanced or metastatic breast cancerJPRN-UMIN000009568General and Gastroenterological Surgery, Osaka Medical College35